rs, though, still get a safeguard: if the acquisition isn’t completed by the applicable deadline, the fixed-rate notes must be redeemed at 101% of face value plus accrued interest. In plain English, that clause puts a deadline on the “deal risk” and turns delays into a direct cost for the issuer.
Why should I care?
For markets: Boston Scientific’s 101% redemption clause puts a price on deal delays.
A mandatory redemption at 101% changes the risk profile of the fixed-rate tranches. If the Penumbra deal drags past the deadline, bondholders aren’t stuck holding longer-dated credit while uncertainty lingers; they get paid out at a small premium, which limits extension risk (the risk that your money is tied up for longer than expected). That can support tighter pricing than a plain long-maturity bond, because part of the financing starts to look more like a time-limited bridge with built-in protection. The trade-off is on Boston Scientific’s side: a missed timeline can trigger an early payoff at 101%, turning “deal timing” into an explicit cash penalty that raises the all-in cost of funding.
